CAR T cell therapy, a cutting-edge approach in immuno-oncology, involves engineering a patient’s own T cells to express receptors that specifically target cancer cells. Despite its success in blood cancers, many patients experience suboptimal responses or disease recurrence, underscoring the urgent need for strategies that augment T cell persistence and cytotoxicity without imposing additional treatment-related burdens. Maayan Levy, the study’s lead investigator and an Assistant Professor of Pathology at Stanford, approached this problem through a metabolic lens, hypothesizing that nutrient availability and energy substrate utilization might influence therapeutic outcomes.

The study meticulously evaluated the impact of diverse dietary regimens on CAR T cell function using murine cancer models. Diets ranging from high-fiber and Western-style to ketogenic were tested, revealing that only ketogenic feeding consistently improved tumor control when combined with CAR T therapy. This diet elevates circulating BHB levels, pinpointing the ketone body as a key modulator. To parse out whether direct BHB supplementation could recapitulate these benefits, the research team administered BHB alone, observing marked enhancements in CAR T cell expansion and tumor clearance—effects strikingly similar to the full ketogenic diet intervention.

Intriguingly, the BHB-mediated improvements depended strictly on the presence of engineered CAR T cells, as non-engineered T cells showed negligible response to BHB. Mechanistically, stable isotope metabolic tracing confirmed that CAR T cells actively metabolize BHB by incorporating it into the tricarboxylic acid (TCA) cycle, thus fueling mitochondrial respiration. Enhanced oxygen consumption rates and increased ATP production in BHB-treated CAR T cells validate this metabolic reprogramming, which bolsters the cells’ bioenergetic capacity and resilience against tumor-associated metabolic stress.

On a genomic level, single-cell transcriptomic profiling illuminated shifts induced by BHB exposure—CAR T cells upregulated genes associated with activation and cytotoxic function while downregulating exhaustion markers. Chromatin accessibility mapping using ATAC-seq and CUT&RUN further showed that BHB remodels the epigenetic landscape to favor regions linked to energy metabolism and immune effector pathways. These coordinated molecular changes underpin the enhanced antitumor efficacy observed in vivo.

To firmly establish that the therapeutic benefit hinges on metabolic consumption rather than a mere signaling effect of BHB, the investigators employed CRISPR gene editing to disrupt BDH1, the enzyme responsible for converting BHB into usable energy. Loss of BDH1 abrogated the BHB-induced enhancements in CAR T cells, underscoring the necessity of ketone metabolism for functional improvement.

This groundbreaking work not only underscores the untapped potential of metabolic interventions to extend the benefits of CAR T cell therapy but also offers a practically accessible adjunct approach. Ketogenic diets, while effective, present adherence challenges in cancer patients due to nutritional complexities and appetite disturbances. BHB supplementation circumvents these issues, potentially providing a safe, scalable, and cost-effective means to invigorate CAR T cells without genetic modification.

Looking ahead, a clinical trial assessing BHB supplementation in patients with Large B-cell Lymphoma is already underway, setting the stage for translation of these preclinical insights into clinical practice. The prospect of enhancing immunotherapy through metabolic support aligns with a growing recognition that cancer treatment requires multidimensional strategies—integrating genetics, immune modulation, and now bioenergetic optimization—to surmount tumor immune evasion.

Levy’s team exemplifies how dissecting the metabolic underpinnings of immune cell function can open novel avenues for therapy, particularly when genetic engineering approaches reach their limitations. Their findings advocate for leveraging innate cellular biochemistry via ketone bodies to reinforce T cell vitality and function, enhancing durable cancer control in resistant and difficult-to-treat malignancies like pancreatic cancer.

This study represents a paradigm shift, suggesting that simple, natural metabolites—far from passive bystanders—play active roles in shaping immune cell performance. As the field moves toward more sophisticated and patient-friendly immunotherapies, integrating metabolic supplementation could redefine standard of care, offering renewed hope to patients battling relapsed or refractory cancers.

The convergence of immunology, metabolism, and oncology embodied in this work is emblematic of a broader scientific renaissance that recognizes the interdependence of biological systems. Metabolic reprogramming in CAR T cells, harnessed through endogenous molecules like BHB, points to a revolutionary yet elegantly natural tactic to amplify immunotherapy’s reach and efficacy.

In summary, this landmark research elevates β-hydroxybutyrate from a mere metabolic byproduct to a central player in bolstering CAR T cell metabolism and function. The clinical implications are profound, promising a future in which metabolic interventions enhance the power of cellular therapies, potentially transforming outcomes across a spectrum of challenging cancers.

Subject of Research: Animals

Article Title: β-hydroxybutyrate enhances the metabolic fitness of CAR T cells in cancer

News Publication Date: 6-Mar-2026

Web References:
https://doi.org/10.1016/j.cell.2026.02.004

References:
Liu, S., Guruprasad, P., Ramasubramanian, R., Madhu, B., Paruzzo, L., Han, K., Kelly, A., Shestov, A., Xu, H.N., Carturan, A., Zhou, C., Amses, K.R., Afriat, A., Litichevskiy, L., Lin, J., Dubowitz, E., Tangal, N., Zhang, J., McSween, A., Tan, M., Stella, F., Lee, A., Nason, S., Hua, X., Schneider, M., Sleeman, M., Zhang, Y., Gabrielli, G., Yang, Z., Pajarillo, R., Patel, R., Ghilardi, G., Patel, V., Joshi, A., Jiang, S., Jiang, Y., Porazzi, P., Tchou, J.C., Keith, B., Li, M., Chong, E., Schuster, S.J., Milone, M., Rabinowitz, J., O’Connor, R., Thaiss, C.A., Levy, M., & Ruella, M. (2026). β-Hydroxybutyrate Enhances the Metabolic Fitness of CAR T Cells in Cancer. Cell. https://doi.org/10.1016/j.cell.2026.02.004

Image Credits: Arc Institute

Keywords: Metabolites, Immunotherapy

The manufacturing of CAR T cells is not merely a mechanical process; rather, it is meticulously tailored to enhance the yield and closely monitor the inherent qualities of the T cells being produced. Among the critical determinants of these qualities is metabolic fitness, which represents the ability of T cells to utilize nutrients efficiently and generate energy for optimal functioning. Despite its importance, the specific metabolic requirements of T cells throughout the various stages of the CAR T cell manufacturing process remain largely underexplored. This gap in knowledge represents a significant hurdle for researchers aiming to refine CAR T cell therapies for solid tumors.

In a groundbreaking study, researchers employed optical metabolic imaging (OMI), a cutting-edge, non-invasive, label-free technique, to delve into the metabolic dynamics of CAR T cells throughout their production. By utilizing OMI, investigators can directly assess and visualize the metabolic activity of single cells in real time, rendering it an invaluable tool for understanding how the cells’ environments—particularly media composition—affect their metabolic profiles, activation kinetics, and phenotypes.

The researchers found that the nutrient composition of the media employed during the manufacturing process profoundly influences the metabolic state of CAR T cells. Variations in the concentrations of key metabolites lead to distinct cellular responses that can impact the efficiency of the T cell activation and expansion process. For instance, certain nutrient profiles have been shown to enhance T cell vigor, allowing for a more robust activation response, which is crucial for generating an effective anti-tumor immune response. The researchers’ findings underscore the potential of OMI in not only monitoring but also optimizing media conditions for maximal T cell performance.

Furthermore, the study revealed that OMI could provide insights into the cell cycle progression of CAR T cells. By analyzing metabolic characteristics, the researchers were able to discern between different stages of the cell cycle. This capability offers a transformative approach to assessing which T cells are primed for expansion and activation, enabling more strategic selection during the manufacturing process.

Another significant outcome of this investigation was the demonstration of OMI’s predictive power regarding gene transfer methods used in CAR T cell production, specifically in the contexts of viral transduction and electroporation-based CRISPR/Cas9 approaches. By correlating OMI measurements with cellular responses post-gene transfer, the researchers were able to establish criteria for optimized gene transfer conditions, facilitating improved integration and expression of CARs within T cells.

In particular, this analysis was crucial for the CRISPR-edited anti-GD2 CAR T cell model, a promising candidate for treating neuroblastoma. The metabolic signatures identified by OMI indicated an oxidative metabolic phenotype that is associated with enhanced in vivo activity against tumor cells. These findings are pivotal as they not only highlight the importance of metabolic profiling in CAR T cell manufacturing but also help pinpoint the specific metabolic pathways that contribute to heightened anti-tumor efficacy.

What is particularly compelling about the results of this study is the implication that iterative adjustments to the manufacturing process, informed by OMI data, could lead to significant improvements in CAR T cell performances. Researchers are increasingly recognizing that the optimization of metabolic fitness is not simply beneficial but rather essential to developing therapeutics capable of overcoming the limitations posed by the solid tumor microenvironment.

By leveraging OMI as a robust analytical framework, researchers now have the capacity to monitor and optimize manufacturing practices to yield CAR T cells that exhibit superior metabolic fitness. This approach paves the way for more personalized and effective cancer therapies, as the interplay between cell metabolism and therapeutic outcomes becomes increasingly elucidated.

The potential implications of OMI extend far beyond the realm of CAR T cell manufacturing; they also suggest opportunities for advancing other cellular therapies. As researchers seek to enhance the performance of not only CAR T cells but also other immune cell types, metabolic imaging could become a standard part of the analytical toolkit in the field of regenerative medicine and immunotherapy.

Ultimately, the research underscores a paradigm shift in how we think about the production and optimization of cellular therapies. By recognizing the significance of metabolic dynamics, scientists can enhance CAR T cell efficacy against solid tumors beyond current limitations, heralding a new era in personalized cancer treatment. The advancements captured in this research not only advance the field of CAR T therapy but also serve as a beacon of hope for patients battling solid tumor malignancies.

In conclusion, the integration of optical metabolic imaging in CAR T cell manufacturing represents a pivotal development in the quest to overcome the formidable challenges associated with solid tumors. By focusing on cellular metabolic fitness and employing advanced imaging techniques, researchers can refine treatment modalities and elevate the therapeutic efficacy of engineered T cells. As the field progresses, the potential to translate these findings into clinical practice could revolutionize cancer therapy, delivering significant benefits to patients facing the bleakest of prognoses.

Subject of Research: The metabolic optimization of CAR T cell therapies for solid tumors using optical metabolic imaging.

Article Title: Label-free metabolic imaging monitors the fitness of chimeric antigen receptor T cells.

Article References:

Pham, D.L., Cappabianca, D., Forsberg, M.H. et al. Label-free metabolic imaging monitors the fitness of chimeric antigen receptor T cells. Nat. Biomed. Eng (2025). https://doi.org/10.1038/s41551-025-01504-7

Image Credits: AI Generated

DOI: 10.1038/s41551-025-01504-7

Keywords: CAR T cell therapy, optical metabolic imaging, solid tumors, immunotherapy, metabolic fitness, gene transfer, neuroblastoma, CRISPR/Cas9, tumor microenvironment, cellular manufacturing.